secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2025-03-21T23:59:59+00:00
Accession:  0001437749-25-008617
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart reports FY2024 net loss $66.9M, revenue $28.7M; initiates Phase 1 norovirus trial
--------------------------------------------------------------------------------

- Net loss $66.9M ($0.33/sh) vs $82.5M in 2023; revenue $28.7M (up from $7.4M).
- Cash $51.7M provides runway into Q4 2025; workforce reduced ~10% after COVID trial stop-work order.
- Phase 1 trial of second-gen norovirus vaccine started; topline data expected mid-2025.
- COVID-19 Phase 2b sentinel cohort enrolled; U.S. government stop-work order issued, only per-protocol follow-up allowed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774925008617/0001437749-25-008617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774925008617/vxrt20250320_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-008617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer